Indian court upholds Natco's compulsory license for Bayer's Nexavar; Valeant makes FTC filing on proposed Allergan takeover;

@FiercePharma: Top-read on FP Monday: Riled by $84,000 Sovaldi, Senate panel digs into Gilead's Pharmasset buy. Article | Follow @FiercePharma

@EricPFierce: Too bad Pfizer couldn't point to the Cork jobs when it was being savaged over its run at AstraZeneca. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Teva rebel investor Landa's gearing up for a proxy fight--and he can win, he says. Report | Follow @CarlyHFierce

> The High Court in Bombay, India, has upheld a compulsory license for Natco to manufacture a generic of Bayer's cancer drug Nexavar. Story

> Valeant Pharmaceuticals ($VRX) said today that it has filed a premerger notification with the U.S. Federal Trade Commission for its proposed acquisition of Allergan. Announcement

> Janssen will sell Pfizer's antidepressant Efexor XR in South Korea. Story

> GlaxoSmithKline ($GSK) has recalled about 10,600 bottles of its Panadol painkiller in Puerto Rico because the packaging was not found to be child-resistant. Story

> Salix Pharmaceuticals ($SLXP) and Progenics Pharmaceuticals ($PGNX) announced that the FDA has informed them it can approve Relistor subcutaneous injection for the treatment of opioid-induced constipation (OIC) in cancer patients based on the data they have submitted. Report

> Mallinckrodt ($MNK) and Questcor Pharmaceuticals ($QCOR) have set Aug. 14 shareholder meetings to vote on their proposed merger. Release

> Portugal-based Bial and Latin-American focused moksha8 have approved a license for the commercialization of eslicarbazepine acetate in Brazil and Mexico for the treatment of epilepsy. Release

Medical Device News

@FierceMedDev: Abbott continues evolution toward devices, planning to sell generics portfolio for $5.3B. Article | Follow @FierceMedDev

@StacyALawrence: RT @EmilyMFierce: I wrote a piece for about what it's like to have a rare voice disorder. Story | Follow @StacyALawrence

@VarunSaxena2: ICYMI: FDA panel recommends stronger labeling, limiting use of power morcellation--agency may go further. Story | Follow @VarunSaxena2

@MichaelGFierce: Trending on FierceDrugDelivery: , MicroCHIPS develop remote-controlled with on-off delivery. Article | Follow @MichaelGFierce

@EmilyWFierce: Boston Scientific wins CE mark for next-generation drug-coated balloon catheter. Article | Follow @EmilyWFierce

> Novartis and Google team up to develop smart contact lenses. Article

> Abbott CEO: 'I don't feel the pressure to invert.' More

> St. Jude shells out $200M for chronic pain therapy manufacturer NeuroTherm. Report

Biotech News

@FierceBiotech: Targacept's Alzheimer's hopeful misses the mark in Phase II. Report | Follow @FierceBiotech

@DamianFierce: I love how Twitter has long been criticizing the froth in biotech but then Yellen steps in and it's like, Yo. | Follow @DamianFierce

@EmilyMFierce: Here's what reporters--and you--should look for in scientific studies. More from U.S. News | Follow @EmilyMFierce

> La Jolla leaps on NASH fervor thanks to some preclinical success. News

> Why isn't New York City a biotech hub? More

> Novartis plans to test Alzheimer's drugs in patients without symptoms. Story

Biotech Research News

> Genetic variant may protect against Alzheimer's. More

> Scientists reprogram stem cells into blood cells. Story

> Compound prevents blindness, diabetes in rodents. More

> Eli Lilly Alzheimer's study shows combo therapy clears more amyloid in mice. Article

> Vaccine prevents anthrax infection in preclinical tests. Item

Pharma Manufacturing News

> Glenmark to build $100M plant in North America. News

> Purdue moves forward with $59M plant in North Carolina. Item

> GSK investing $25M for Codexis manufacturing technology. Article

> Job-cutting Pfizer saves 100 jobs in U.K. Story

> PhRMA, BIO, GPhA ask court to trash California drug disposal law. Report

And Finally... Sanofi ($SNY) has donated $2.5 million to the Milken Institute School of Public Health at George Washington University in Washington, DC. Announcement

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.